

A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- at least 18 years old - diagnosis of non-small cell lung cancer (NSCLC) - tumor size between 1 and 4 cm in size - had a complete surgical resection of stage I NSCLC between 4-12 weeks ago - able to walk and carry out basic activities of living - women are willing to use highly effective birth control for 120 days after last dose of study drug - certain laboratory values are required (study staff will review)

Exclusion Criteria:

- chemotherapy, radiation therapy, or immunotherapy for the treatment of this lung cancer - active additional cancer that is progressing or has required treatment within the past 3 years - diagnosis of immunodeficiency or receiving chronic steroid therapy - women who are pregnant or breast feeding - other active diseases (study staff will review)

Conditions & Interventions

Conditions:

Cancer

Keywords:

Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Clinics and Surgery Center (CSC)

More Information

Description: The primary objective is to evaluate whether the addition of adjuvant Pembrolizumab following surgical resection improves disease free survival compared with observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm in size, regardless of PD-L1 TPS score.

Contact(s): Amit Kulkarni - kulkarni@umn.edu

Principal Investigator: Amit Kulkarni

IRB

Number: STUDY00010745

System ID: 29878

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.